ClinicalTrials.gg
CompletedNCT04905914ABOYA-119Updated Aug 4, 2026

Study Of ATRN-119 In Patients With Advanced Solid Tumors

A Phase 1/2 interventional study of ATRN-119 in Advanced Solid Tumor, sponsored by Aprea Therapeutics. Completed at 7 sites in United States. Open to participants aged 12 Years and older. Per ClinicalTrials.gov, last updated 2026-08-04.

Sponsored by Aprea Therapeutics · Phase 1/2, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
43
Allocation
Non-randomized
Ages
12 Years and older
Sex
All
01

Study summary

The purpose of this study is to assess the safety and effectiveness of ATRN-119 through the performance of a Phase 1/2a, open-label, safety, PK, and preliminary efficacy study of oral ATRN-119 in patients with advanced solid tumors.

02

Conditions studied

  • Advanced Solid Tumor
03

In context

Lead sponsor

Aprea Therapeutics is the lead sponsor of 12 studies on the registry; 1 is open to participants now.

Of its 8 completed or terminated interventional studies of FDA-regulated products, 7 (88%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
12 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • DNA damage response (DDR) mutations documented in the past medical record or confirmed during the screening period.
  • defined by 1.1.
  • ≥ 3 months.
  • Subject must be capable of oral administration of study medication.

Exclusion criteria

Exclusion Criteria:

  • Patient has had a cytotoxic chemotherapy, immunotherapy, radiotherapy or other targeted therapies within 4 weeks.
  • Surgical procedure performed within 7 days prior to first scheduled dose of ATRN-119.
  • Concomitant treatment with strong inhibitors or inducers of and CYP2D6.
  • Known infection (HIV).
  • Subjects with active viral or bacterial infections and/or receiving systemic antibiotics or anti-viral medications.
  • Current or past diagnosis of leukemia within the past 5 years.
  • Prior radiotherapy at the target lesion unless there is evidence of disease progression.
  • Known or clinical evidence of CNS involvement that is not stable for previous 1 month by radiology documentation (magnetic resonance imaging [MRI] brain).
  • History of non-malignant gastronintestinal (GI) bleeding, gastric stress ulcerations, or peptic ulcer disease within the past 3-months.
  • Patient has uncontrolled hypertension at time of enrollment.
  • Complete left bundle branch block (LBBB), bifascicular block (right bundle branch block [RBBB] with either left anterior hemiblock or left posterior hemiblock).
  • Any ST segment and/or T-wave abnormalities.
  • Myocardial infarction or unstable angina pectoris within 6 months prior to starting study medication.
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
43 participants (actual)

Study arms

  • Experimental
    50mg ATRN-119

    Once daily oral administration.

    Drug: ATRN-119

  • Experimental
    100mg ATRN-119

    Once daily oral administration.

    Drug: ATRN-119

  • Experimental
    200mg ATRN-119

    Once daily oral administration.

    Drug: ATRN-119

  • Experimental
    350mg ATRN-119

    Once daily oral administration.

    Drug: ATRN-119

  • Experimental
    400mg ATRN-119

    Twice daily oral administration.

    Drug: ATRN-119

  • Experimental
    1100mg ATRN-119

    Once daily oral administration

    Drug: ATRN-119

  • Experimental
    1300mg ATRN-119

    Once daily oral administration

    Drug: ATRN-119

  • Experimental
    1500mg ATRN-119

    Once daily oral administration

    Drug: ATRN-119

  • Experimental
    650mg ATRN-119

    Twice daily oral administration.

    Drug: ATRN-119

  • Experimental
    750mg ATRN-119

    Twice daily oral administration.

    Drug: ATRN-119

  • Experimental
    550mg ATRN-119

    Once or twice daily oral administration

    Drug: ATRN-119

  • Experimental
    800 mg ATRN-119

    Once daily oral administration

    Drug: ATRN-119

Interventions

  • DrugATR Inhibitor ATRN-119Studies of ATR Inhibitor ATRN-119ATR Inhibitor ATRN-119 pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    ATRN-119 is a capsule formulation that will be supplied as 50 mg and 100 mg capsules packed in sealed plastic bottles (n=30) and dispensed by the site pharmacist in combinations to provide the appropriate dose.

06

What researchers measure

Primary outcomes

  1. Treatment Emergent Adverse Events (TEAEs) will be collected and evaluated based on summary statistics

    Treatment-emergent AEs (TEAEs) will be collected and Clinical Laboratory Evaluations will be performed

    Time frame: Day 1 to Day 28

07

Study locations

7 sites
  • Yale Cancer Center
    New Haven, Connecticut 06520-8028, United States
  • University Hospitals, Cleveland Medical Center
    Cleveland, Ohio 44106, United States
  • Jordan Center for Gynecologic Oncology at Penn Perelman Center for Advanced Medicine
    Philadelphia, Pennsylvania 19104, United States
  • Mary Crowley Cancer Research
    Dallas, Texas 75230, United States
  • NEXT- Oncology Dallas
    Irving, Texas 75039, United States
  • NEXT Oncology- San Antonio
    San Antonio, Texas 78229, United States
  • NEXT Oncology- Virginia
    Fairfax, Virginia 22031, United States
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Jan 2023 to primary completion in Mar 2026, 38 months.

How these figures are worked out, and which studies are left out of them.

Registered
May 17, 2021
First posted
May 28, 2021
StartActual
Jan 9, 2023
Primary completionActual
Mar 9, 2026
CompletionActual
Mar 9, 2026
Last update
Aug 4, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 4, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04905914
Lead sponsor
Aprea Therapeutics
Responsible party
Sponsor
First posted
May 28, 2021
Start date
Jan 9, 2023
Primary completion
Mar 9, 2026
Completion
Mar 9, 2026
Last update
Aug 4, 2026

Study contacts

Crystal Miller, RN BSN
study director · Aprea Therapeutics Inc

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: ATR Inhibitor ATRN-119

Start the discussion